首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   6446篇
  免费   599篇
  国内免费   152篇
耳鼻咽喉   37篇
儿科学   93篇
妇产科学   148篇
基础医学   1130篇
口腔科学   109篇
临床医学   433篇
内科学   942篇
皮肤病学   64篇
神经病学   618篇
特种医学   174篇
外科学   606篇
综合类   818篇
预防医学   474篇
眼科学   629篇
药学   455篇
  7篇
中国医学   137篇
肿瘤学   323篇
  2023年   138篇
  2022年   180篇
  2021年   293篇
  2020年   363篇
  2019年   273篇
  2018年   282篇
  2017年   290篇
  2016年   284篇
  2015年   267篇
  2014年   493篇
  2013年   479篇
  2012年   389篇
  2011年   379篇
  2010年   333篇
  2009年   307篇
  2008年   244篇
  2007年   241篇
  2006年   228篇
  2005年   179篇
  2004年   218篇
  2003年   144篇
  2002年   123篇
  2001年   99篇
  2000年   85篇
  1999年   100篇
  1998年   58篇
  1997年   61篇
  1996年   65篇
  1995年   68篇
  1994年   48篇
  1993年   47篇
  1992年   42篇
  1991年   35篇
  1990年   27篇
  1989年   26篇
  1988年   30篇
  1987年   28篇
  1986年   23篇
  1985年   42篇
  1984年   41篇
  1983年   25篇
  1982年   23篇
  1981年   25篇
  1980年   25篇
  1979年   15篇
  1978年   7篇
  1977年   8篇
  1976年   9篇
  1974年   2篇
  1973年   2篇
排序方式: 共有7197条查询结果,搜索用时 62 毫秒
1.
目的:探讨近视儿童配戴多区正向光学离焦镜片后的主观视觉质量,并与角膜塑形镜、单焦点镜 片相比较。方法:前瞻性临床研究。收集2020年7—10月在南宁爱尔眼科医院视光中心配戴多区 正向光学离焦镜片31例(31眼)(DIMS组)、OK镜32例(32眼)(OK镜组)、单焦点镜片30例(30眼) (SV组)共93例(93眼)近视患者。配戴矫正镜片1个月后,采用Oculus视功能检查仪对3组进行全 程视力、对比敏感度、中间视觉、眩光、立体视等主观视觉质量检查。数据采用单因素方差分析、 卡方检验、秩和检验、Spearman相关性分析等方法进行分析。结果:3组患儿戴镜后近、远视力相 对于基线期变化值的差异均无统计学意义。在近、远立体视锐度当中3组差异无统计学意义,3组 在600″~200″立体视视锐度的人数分别都是最少的。3 组之间的对比敏感度差异有统计学意义 (F=17.96, P<0.001),合格例数最多的DIMS组有20例(65%)被检者对比敏感度≤15%。DIMS组在 有无眩光情况下,对比度等级(1:2.7、1:2.0)的通过率均高于OK镜组、SV组,且1:2.0对比度等级更 为明显,差异均有统计学意义(均P<0.001)。立体视锐度与年龄呈负相关(r=-0.30, P=0.008),与 屈光度数无相关性。眩光与对比敏感度间呈正相关(r=0.64, P<0.001),与性别、年龄、屈光度分析 均无相关性。结论:多区正向光学离焦镜片相对于角膜塑形镜及单焦点镜片而言,可提供更好的主 观视觉质量,有好的舒适性和安全性。  相似文献   
2.
目的:分析子野个数限值对宫颈癌固定野调强放疗(fixed-field intensity-modulated radiotherapy,ff-IMRT)计划的影响,寻求最优的子野个数限值。方法:选取10例接受ff-IMRT的宫颈癌患者,基于Monaco 5.11.03计划系统,以45 Gy/25 f处方剂量分别对同一患者设计8种ff-IMRT计划(ff-IMRT计划依据子野个数限值命名,子野个数限值分别为40、60、70、80、100、120、130、150),采用SPSS 20.0软件比较除plan100之外7个ff-IMRT计划与plan100剂量学参数、优化时间和治疗参数的差异。结果:8种ff-IMRT计划归一化后,plan40和plan60的D2%、Dmin、CI和HI均劣于plan100(P<0.05)。8种ff-IMRT计划均能较好保护危及器官(organ at risk,OAR)和正常组织。plan40小肠V45;plan40和plan60小肠D2cc,直肠、膀胱V45、D40%,两侧股骨头V40和正常组织 V35、V40均高于plan100(P<0.05)。plan40和plan60优化时间、治疗参数均优于plan100(P<0.05);plan120、plan130和plan150子野面积、子野个数(51~150 cm2和>150 cm2)和出束时间均劣于plan100(P<0.05)。结论:子野个数限值为70~100时,ff-IMRT计划能兼顾剂量学参数满足临床要求、优化时间和治疗参数最优化,建议在设计宫颈癌ff-IMRT计划时在该范围内设置子野个数限值。  相似文献   
3.
PurposeTo study, from a U.S. payer’s perspective, the economic consequences of drug-coated balloon (DCB) versus standard percutaneous transluminal angioplasty (PTA) use for the treatment of stenotic lesions in dysfunctional hemodialysis arteriovenous fistulae.Materials and MethodsCost differences between DCBs and PTA at year 1 and beyond were calculated via 2 methods. The first approach used the mean absolute number of trial-observed access circuit reinterventions through 12 months (0.65 ± 1.05 vs 1.05 ± 1.18 events per patient for DCBs and PTA, respectively) and projected treatment outcomes to 3 years. The second approach was based on the trial-observed access circuit primary patency rates at 12 months (53.8% vs 32.4%) and calculated the cost difference on the basis of previously published Medicare cost for patients who maintained or did not maintain primary patency. Assumptions regarding DCB device prices were tested in sensitivity analyses, and the numbers needed to treat were calculated.ResultsUsing the absolute number of access circuit reinterventions approach, the DCB strategy resulted in an estimated per-patient savings of $1,632 at 1 year and $4,263 at 3 years before considering the DCB device cost. The access circuit primary patency approach was associated with a per-patient cost savings of $2,152 at 1 year and $3,894 at 2.5 years of follow-up. At the theoretical DCB device reimbursement of $1,800, savings were $1,680 and $2,049 at 2.5 and 3 years, respectively. The one-year NNT of DCB compared to PTA was 2.48.ConclusionsEndovascular therapy for arteriovenous access stenosis with the IN.PACT AV DCB can be expected to be cost-saving if longer follow-up data confirm its clinical effectiveness.  相似文献   
4.
张俊友  轩安武  阮狄克 《中国骨伤》2022,35(11):1104-1108
颈椎前路椎间盘切除融合术(anterior cervical discectomy and fusion,ACDF)应用于临床近百年,取得了良好的临床疗效,被认为是治疗颈椎病的金标准。但融合术后邻近节段退变(adjacent segment degeneration,ASDeg)受到越来越多的关注,关于其发生机制的争论主要集中在融合术导致邻近节段生物应力的改变与年龄相关的自然退变。融合术后发生ASDeg将严重影响手术的中远期疗效,部分患者甚至需要二次手术治疗。为了降低甚至避免ASDeg的发生,临床上出现许多新的技术,诸如保留运动节段的人工椎间盘置换术,新兴的细胞移植技术等,但临床疗效仍需要大量的研究进行证实。因此,发现融合术后发生ASDeg的危险因素对于临床开展融合手术具有重要的意义。目前对于ASDeg危险因素的研究仍无统一认识,本文将从颈椎前路融合术后发生ASDeg的危险因素的研究进展及相应应对措施作一综述,以指导临床实践。  相似文献   
5.
IntroductionAnti-methicillin-resistant Staphylococcus aureus (MRSA) agents have different doses and administration periods. Thus, it is difficult to evaluate antimicrobial use (AMU) of anti-MRSA agents using defined daily doses per 1000 inhabitants per day (DID) or days of therapy per 1000 inhabitants per day (DOTID). This study aimed to evaluate the relationship between anti-MRSA agent use and resistant bacteria using the number of patients per 1000 inhabitants per day (PID) as an alternative index of AMU.MethodsAMU data for anti-MRSA agents were collected from the National Database of Health Insurance Claims and Specific Health Checkups (NDB) in 2016. The relationship between PID and DID or DOTID was evaluated. The number of patients with MRSA isolated was obtained from Japan Nosocomial Infections Surveillance, and their correlation with PID was analyzed. The rate of anti-MRSA agent use in each prefecture was investigated.ResultsPID showed a significant linear relationship with both DID and DOTID (all p < 0.0001). PID was significantly correlated with the number of patients with MRSA isolated. Additionally, the rate of anti-MRSA agent use was markedly different in each region.ConclusionsPID is not affected by doses and administration periods, and thus may be an alternative index for the selective pressure of antibiotics. Evaluating AMU using PID based on NDB data will help in the development of effective antimicrobial resistance measures.  相似文献   
6.
ObjectiveEach pulmonary segment is an anatomical and functional unit. However, it is fundamentally difficult to precisely distinguish every pulmonary segment using the conventional pulmonary intersegmental planes from computed tomography images. Building arteriopulmonary segments is likely to be an effective way to identify pulmonary segments.MethodsThe thoracic computed tomography images of 40 patients were collected. The anatomic structures of interest were extracted in the transverse, sagittal, and coronal planes using the semi-automated segmentation tools provided by Amira software. The intrapulmonary vessels were subsequently segmented and reconstructed. The distributions of the pulmonary arteries, veins, and bronchi were observed. In patients with pulmonary masses, the mass was also reconstructed.ResultsThe three-dimensional reconstructed images showed the branches of the pulmonary artery ramified up to their eighth order covering the entire lung as well as evident intersegmental gaps without pulmonary arteries. The segmental artery was closely accompanied by the segmental bronchi in 486 pulmonary segments (90% of total number of segments). The size and spatial location of the pulmonary mass within a pulmonary segment were also clearly visible.ConclusionsDemarcation of arteriopulmonary segments can be used to precisely distinguish every pulmonary segment and provide its detailed anatomical structure before pulmonary segmentectomy.  相似文献   
7.
8.
Background RAS short variant (SV) mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (EGFRmAb). However, the clinical implications for RAS amplification (RASa) as a biomarker for anti‐EGFR therapy in CRC remain ill defined.MethodsGenomic analysis was performed using the Foundation Medicine (FM) comprehensive genomic profiling database of 37,233 CRC cases. Clinical outcomes were assessed using two independent cohorts: the City of Hope (COH) cohort of 338 patients with metastatic CRC (mCRC) and the Flatiron Health–FM real‐world clinicogenomic database (CGDB) of 3,904 patients with mCRC.Results RASa was detected in 1.6% (614/37,233) of primarily mCRC. RASa 6–9 (n = 241, 39%), 10–19 (n = 165, 27%), and ≥ 20 (n = 209, 34%) copy number subsets had co‐RAS SV/BRAF V600E in 63%/3%, 31%/0.6%, and 4.8%/0% of cases, respectively. In the COH cohort, six patients with RASa (13–54 copies) received EGFRmAb, four of six had progressive disease, two had stable disease, and median time to treatment discontinuation (TTD) was 2.5 months. Of the CGDB EGFRmAb‐treated patients, those with RASa (n = 9) had median TTD of 4.7 months and overall survival (OS) of 11.4 months, those with RAS SV (n = 101) had median TTD and OS of 5.3 and 9.4 months, and those with RAS/BRAF wild‐type (n = 608) had median TTD and OS of 7.6 and 13.7 months.ConclusionPatients with RASa without RAS mutations (1.1% of mCRC) may have poor outcomes on EGFRmAb, although numbers herein were small, and interpretation is confounded by combination chemotherapy. Larger independent studies are warranted to determine if RASa, including degree of amplification, may act similarly to RAS mutation as a resistance mechanism to EGFRmAb therapies.Implications for PracticeGenomic data suggest that RAS amplification occurs as the sole RAS/RAF alteration in >1% of colorectal cancer cases and that degree of amplification inversely correlates with co‐occurring MAPK pathway alterations. Preliminary clinical evidence suggests that RAS amplification may function similarly to RAS mutation as a negative predictor of benefit from anti‐epidermal growth factor receptor therapies in colorectal cancer. More clinical data are needed, and comprehensive genomic profiling, including detection of RAS amplification, should be used in trial design to inform therapy selection.  相似文献   
9.
IntroductionComputed tomography (CT) numbers are used in radiological diagnosis, attenuation correction and radiotherapy treatment planning. Modern CT scanners use iterative reconstruction methods instead of the traditional filtered back projection (FBP). Hence, the investigation of CT number accuracy with image reconstruction techniques and X-ray tube potential (kVp) used in CT is warranted. The aim of this study is to evaluate the effect of Sinogram Affirmed Iterative Reconstruction (SAFIRE) Technique and image acquisition at different tube potentials on CT numbers of different tissue equivalent materials.MethodsImages of the Computerised Imaging Reference System Model 062M Electron Density Phantom were acquired at different tube potentials and reconstructed using FBP and different strengths of SAFIRE. Average CT numbers, in circular regions of interest, and their standard deviations were used to investigate any dependence of CT numbers on tube potentials and/or image reconstruction technique using non-parametric statistical tests with p-values set at 0.05.ResultsStatistically significant differences in CT numbers were not observed (p > 0.091) between the different image reconstruction techniques. CT number of bone equivalent materials increased significantly (p < 0.015), by up to 400 Hounsfield Units, when tube potential was decreased. Such extent of CT number change over the tube potentials range used in this study may influence diagnostic outcomes in lung nodule, contrast enhanced and calcium score studies. For all other tissue equivalent materials, the CT number did not change significantly for different tube potentials. Linear relationship was observed between CT numbers and electron densities.ConclusionThe study concludes that the CT numbers of all tissues did not change significantly with image reconstruction methods. However, the CT numbers of bone equivalent materials increased with decreasing tube potentials, which may result in misrepresentation of clinical information obtained.Implications for practiceWhen CT images are used to extract quantitative parameters such as calcium score, to characterise lung nodules and contrast enhanced structures, the kVp used for image acquisition should be carefully selected to avoid any misrepresentation of clinical information.  相似文献   
10.
《JACC: Cardiovascular Imaging》2021,14(11):2186-2195
ObjectivesThe purpose of this study was to develop a risk prediction model for patients with nonobstructive CAD.BackgroundAmong stable chest pain patients, most cardiovascular (CV) events occur in those with nonobstructive coronary artery disease (CAD). Thus, developing tailored risk prediction approaches in this group of patients, including CV risk factors and CAD characteristics, is needed.MethodsIn PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) computed tomographic angiography patients, a core laboratory assessed prevalence of CAD (nonobstructive 1% to 49% left main or 1% to 69% stenosis any coronary artery), degree of stenosis (minimal: 1% to 29%; mild: 30% to 49%; or moderate: 50% to 69%), high-risk plaque (HRP) features (positive remodeling, low-attenuation plaque, and napkin-ring sign), segment involvement score (SIS), and coronary artery calcium (CAC). The primary end point was an adjudicated composite of unstable angina pectoris, nonfatal myocardial infarction, and death. Cox regression analysis determined independent predictors in nonobstructive CAD.ResultsOf 2,890 patients (age 61.7 years, 46% women) with any CAD, 90.4% (n = 2,614) had nonobstructive CAD (mean age 61.6 yrs, 46% women, atherosclerotic cardiovascular disease [ASCVD] risk 16.2%). Composite events were independently predicted by ASCVD risk (hazard ratio [HR]: 1.03; p = 0.001), degree of stenosis (30% to 69%; HR: 1.91; p = 0.011), and presence of ≥2 HRP features (HR: 2.40; p = 0.008). Addition of ≥2 HRP features to: 1) ASCVD and CAC; 2) ASCVD and SIS; or 3) ASCVD and degree of stenosis resulted in a statistically significant improvement in model fit (p = 0.0036; p = 0.0176; and p = 0.0318; respectively). Patients with ASCVD ≥7.5%, any HRP, and mild/moderate stenosis had significantly higher event rates than those who did not meet those criteria (3.0% vs. 6.2%; p = 0.007).ConclusionsAdvanced coronary plaque features have incremental value over total plaque burden for the discrimination of clinical events in low-risk stable chest pain patients with nonobstructive CAD. This may be a first step to improve prevention in this cohort with the highest absolute risk for CV events.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号